CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate available and emerging data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant, adjuvant or consolidation therapy for nonmetastatic non-small cell lung cancer (NSCLC).
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor therapy for localized NSCLC with an EGFR mutation, and identify patients for whom this treatment would be warranted.
  • Counsel patients with metastatic NSCLC with EGFR mutations about available therapeutic options.
  • Understand the biology of EGFR exon 20 insertion mutations, and evaluate how recently approved agents should be used in the care of patients with these abnormalities.
  • Assess the efficacy and safety of commercially available and investigational therapies for patients with metastatic NSCLC with ALK or ROS1 rearrangements, and use this information to select first- and later-line therapy.
  • Recollect other oncogenic pathways mediating the pathogenesis of tumors (ie, RET, MET, HER2 and KRAS G12C), and recall published data with agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy, chemobiologic therapy or anti-CTLA-4 antibodies for metastatic NSCLC, and discern how these approaches can be optimally employed in clinical practice.
  • Reflect on investigational agents and strategies currently in testing for lung cancer, and appropriately refer eligible patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and a short post-test, enables the participant to earn up to 2.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/ASCO2023/Lung/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Edward B Garon, MD, MS
  Professor
  Director, Thoracic Oncology Program
  Director, Signal Transduction and Therapeutics Research Program
  David Geffen School of Medicine at UCLA
  Jonsson Comprehensive Cancer Center
  Los Angeles, California
  
  Consulting Agreements: ABL Bio, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Dracen Pharmaceuticals, Eisai Inc, EMD Serono Inc, Gilead Sciences Inc, GSK, Lilly, Merck, Natera Inc, Novartis, Personalis, Regeneron Pharmaceuticals Inc, Sanofi, Shionogi Inc, Xilio Therapeutics, Zymeworks Inc; Contracted Research: ABL Bio, AstraZeneca Pharmaceuticals LP, BioNTech SE, Bristol Myers Squibb, Daiichi Sankyo Inc, Dynavax Technologies, EMD Serono Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, lovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics Inc, Novartis; Data and Safety Monitoring Board/Committee: Nuvalent; Sponsored Independent Medical Education: Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc; Travel: A2 Bio, Novartis.
  
  John V Heymach, MD, PhD
  Professor and Chair
  Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, BrightPath Biotherapeutics Co Ltd, Bristol Myers Squibb, Catalyst Pharmaceuticals, Chugai Pharmaceutical Co Ltd, EMD Serono Inc, Genentech, a member of the Roche Group, GSK, Hengrui Therapeutics Inc, Janssen Biotech Inc, Lilly, Mirati Therapeutics Inc, Nexus Health Systems, Pneuma Respiratory, RefleXion, Sanofi, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Research Support: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Royalties and Licensing Fees: Spectrum Pharmaceuticals Inc.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Consulting Fees: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GSK, Heat Biologics, Merck, Mirati Therapeutics Inc, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Data Safety Monitoring Board or Advisory Board (Co-Chair): Amgen Inc, Oncocyte; Medical Writing: Novartis; Research Funding: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Inovio Pharmaceuticals Inc, Lilly, Merck, Oncocyte, Takeda Pharmaceuticals USA Inc, Trizell; Nonrelevant Financial Relationship: US Department of Veterans Affairs.
  
  Ticiana Leal, MD
  Associate Professor
  Department of Hematology and Oncology
  Director, Thoracic Medical Oncology
  Winship Cancer Institute
  Emory University
  Atlanta, Georgia
  
  Consultant/Advisory Boards: Amgen Inc, AstraZeneca Pharmaceuticals LP, Catalyst Pharmaceuticals, Daiichi Sankyo Inc, Eisai Inc, EMD Serono Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Merck, Novocure Inc, Regeneron Pharmaceuticals Inc, Roche Laboratories Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Advaxis Inc, Bayer HealthCare Pharmaceuticals, Pfizer Inc; Data and Safety Monitoring Board/Committee: OncoC4; Speaker: Aptitude Health, Cardinal Health, Curio Bioscience; Nonrelevant Financial Relationship: ASTRO, GASCO, GRACE, IDEOlogy Health, Medscape, National Cancer Institute, Nebraska Oncology Society, OncLive, Opinions in Lung Cancer, PeerView, SITC, Targeted Oncology.
  
  David R Spigel, MD
  Chief Scientific Officer
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Bristol Myers Squibb, Evidera, Genentech, a member of the Roche Group, GSK, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Molecular Templates, Monte Rosa Therapeutics, Novartis, Novocure Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: AbbVie Inc, Aeglea BioTherapeutics, Agios Pharmaceuticals Inc, Amgen Inc, AnHeart Therapeutics, Apollomics Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Ascendis Pharma, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BIND Therapeutics Inc, BioNTech SE, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Cyteir Therapeutics, Daiichi Sankyo Inc, Denovo Biopharma, Eisai Inc, Elevation Oncology, Endeavor Biomedicines, Erasca, Faeth Therapeutics, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Grail Inc, GSK, Hutchison MediPharma, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Inspirna, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals, Kronos Bio, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lyell Immunopharma, MacroGenics Inc, Merck, Moderna, Molecular Templates, Monte Rosa Therapeutics, Nektar, Novartis, Novocure Inc, Peloton Therapeutics Inc, a wholly-owned subsidiary of Merck & Co Inc, PureTech Health, Razor Genomics, Repare Therapeutics, Seagen Inc, Shenzhen Chipscreen Biosciences Co Ltd, Stemline Therapeutics Inc, Synthekine, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tango Therapeutics, Tarveda Therapeutics, Tesaro, A GSK Company, Tizona Therapeutics Inc, Transgene, Verastem Inc, Zai Lab; Nonrelevant Financial Relationship: UT Southwestern Medical Center.
  
  Helena Yu, MD
  Medical Oncologist
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Janssen Biotech Inc; Research Funding to My Institution: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Novartis, Pfizer Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, Novocure Inc, Regeneron Pharmaceuticals Inc, and Takeda Pharmaceuticals USA Inc.
  
  Release date: June 2023
  Expiration date: June 2024
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.